- Adjusted EPS: Becton Dickinson reported an adjusted EPS of $3.50, surpassing the estimate of $3.31.
- Revenue: The company generated revenue of $4.99 billion, slightly below the estimated $5.08 billion.
- Segment Performance:
- Medical revenue: $2.56 billion (estimate: $2.53 billion)
- Medication Delivery Solutions revenue: $1.12 billion (estimate: $1.1 billion)
- Medication Management Solutions revenue: $840 million (estimate: $832.1 million)
- Pharmaceutical Systems revenue: $594 million (estimate: $597.5 million)
- Life sciences revenue: $1.26 billion (estimate: $1.27 billion)
- Integrated Diagnostic Solutions revenue: $896 million (estimate: $888.9 million)
- Biosciences revenue: $363 million (estimate: $384.2 million)
- Interventional revenue: $1.24 billion (estimate: $1.26 billion)
- Surgery revenue: $376 million (estimate: $380.7 million)
- Peripheral Intervention revenue: $488 million (estimate: $503.4 million)
- Urology and Critical Care revenue: $375 million (estimate: $376 million)
- Fiscal 2024 Guidance Update:
- The company updated its GAAP revenue growth guidance to approximately 3.7%.
- Organic revenue growth guidance is now between 5.0% to 5.25%.
- Adjusted diluted EPS guidance was increased by $0.05 at the midpoint to a range of $13.05 to $13.15, driven by margin performance and outlook.
- Analyst Ratings: 15 buys, 3 holds, 0 sells.
A look at Becton Dickinson and Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts have provided a comprehensive outlook for Becton Dickinson and Co using the Smartkarma Smart Scores. With a balanced score of 3 across multiple factors including Value, Dividend, Growth, Resilience, and Momentum, the company seems to be positioned for stable long-term growth. Becton Dickinson and Co is a global medical technology company focused on the development, manufacturing, and sale of medical devices and instrument systems used across various sectors, including healthcare institutions, research labs, clinical laboratories, pharmaceutical industry, and the general public.
Despite facing average scores across the board, Becton Dickinson and Co‘s consistent performance in key areas like Value, Dividend, Growth, Resilience, and Momentum indicates a solid base for future prospects. The company’s broad reach in the medical technology sector and its role in providing essential products to various industries position it well for sustained growth and stability in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
